News

December 11, 2014December 11, 2014

How to Know and Manage Early Warning Signs of Rheumatoid Arthritis

News

Barbara Griffin, NMD, CNC, Certified Gluten Practitioner and Director of Vital Health, Inc., believes the earlier symptoms of rheumatoid arthritis are managed, the better the disease outcome and odds that ... Read more

December 10, 2014December 10, 2014

Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis Revealed Positive Results

News

Eli Lilly and Company and Incyte Corporation announced that the RA-BEACON Phase 3 study of baricitinib, an investigational drug for RA, improved the ACR20 response (the response that indicates how much a person’s rheumatoid arthritis ... Read more

December 9, 2014December 12, 2014

Lilly / Incyte Arthritis Investigational Drug Baricitinib Achieves Primary Endpoint

News

Eli Lilly and Company and Incyte Corporation have reached the primary endpoint at their joint phase 3 study for an investigational medication for the treatment of rheumatoid arthritis, called RA-BEACON. The phase 3 study ... Read more

December 9, 2014December 9, 2014

Serum Biomarker Correlates to Rheumatoid Arthritis Disease Activity

News

A new study from Brandenburg Technical University Cottbus in Germany has implications both for rheumatoid arthritis patients and the general scientific community. Lead author Dr. Melanie Gruner and principal investigator ... Read more

December 8, 2014December 8, 2014

Testing In Promising Rheumatoid Arthritis Darwin Monotherapy Study Now Underway

News

Galapagos NV announced they completed the recruitment phase for patients with rheumatoid arthritis to enroll their Darwin Phase 2B program evaluating GLPG0634 (filgotinib) as a monotherapy for rheumatoid arthritis. GLPG0634 is a selective inhibitor of JAK1, a key factor in the JAK-STAT ... Read more